Skip to main content

Part of cannabis and investing

The chief executive officer of CannTrust Holdings Inc. says the company hasn’t decided yet whether it will pursue a U.S. stock listing but it is weighing the option.

In early Friday trading, shares of the Vaughan, Ont.-based cannabis grower had jumped nearly 25 per cent since Thursday afternoon, following comments apparently made to investors at an event hosted by GMP Securities that sparked speculation on social media that CannTrust was planning to list on the Nasdaq within 30 to 60 days.

But on Friday morning, CannTrust CEO Eric Paul said that the company hasn’t made a decision to list its shares south of the border.

Story continues below advertisement

“It’s a consideration, but we don’t have a definitive plan for it. No decision has been made to list,” he said in a phone interview on Friday. “The time frame would be 30 to 60 days to get it done. But that doesn’t mean we’re listing in 30 to 60 days.”

The three pot stocks listed in the U.S. – Canopy Growth Corp., Cronos Group Inc. and Tilray Inc. – have been on a tear in recent days, as money from American investors floods the burgeoning space. Investors are betting which Canadian cannabis firm will be next to benefit from the U.S. bump.

Shares of CannTrust jumped 7 per cent early Friday morning to $11.37, rising nearly 70 per cent in value during the past month. By Friday's close, the shares had erased their most recent gains, closing at $10.30.

Coming soon: Cannabis Professional, an authoritative e-mail newsletter tailored specifically for professionals in the rapidly evolving cannabis industry. Sign up now to learn more.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter